AnaptysBio appoints Christopher Murphy CFO ($42,917/mo) and Owen Hughes to board

ANAPTYSBIO, INC

Christopher Murphy appointed CFO effective May 11, 2026; previously CFO at Third Harmonic Bio and Horizon Therapeutics.
Murphy's consulting agreement: $42,916.66 monthly fee, target bonus up to 40% of annual fees, and $1.75M RSU grant vesting over 4 years.
Owen Hughes appointed Class I director effective May 11, 2026; receives initial grant of 11,250 RSUs vesting over 3 years.
Murphy serves as independent contractor; severance provides 9-12 months fee continuation based on termination cause.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher M. Murphy

Chief Financial Officer

ANAB · ANAPTYSBIO, INC

Effective: 2026-05-11
Filed: May 11, 2026, 4:05 PM ET

On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher M. Murphy was appointed as Chief Financial Officer at ANAPTYSBIO, INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.

View on SEC.gov

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001193125-26-216745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.